BSGMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:30):

Stats
本日の出来高	46 190.00
平均出来高	1.21M
時価総額	14.46M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.330
ATR14	$0.0200 (1.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Hrkac Frederick	Buy	500 000	Common Stock
2023-12-28	Hrkac Frederick	Buy	900 000	Restricted Stock Units
2023-12-28	Hrkac Frederick	Buy	600 000	Stock Option (Right to Buy)
2023-11-30	Sieckhaus John	Buy	92 300	Common Stock
2023-11-30	Fleming Gray	Buy	131 900	Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 6 442 688 \| Sell: 40 000

ボリューム相関

長: 0.17 (neutral)

短: -0.38 (neutral)

Signal:(54.537) Neutral

Biosig Technologies Inc 相関

10 最も正の相関
ROIV	0.951
RDFN	0.939
CRNC	0.935
NLSP	0.934
ALGN	0.932
EVCM	0.927
LCAA	0.925
ARAY	0.923
FTIV	0.923
PRQR	0.923

10 最も負の相関
GRIN	-0.94
MTEX	-0.924
RIVN	-0.922
ZENV	-0.919
PIII	-0.916
SGLB	-0.911
OP	-0.909
LHDX	-0.903
SNPX	-0.903
NVTSW	-0.902

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Biosig Technologies Inc 相関 - 通貨/商品

0.06
( neutral )

0.02
( neutral )

0.00
( neutral )

0.12
( neutral )

0.52
( weak )

-0.02
( neutral )

Biosig Technologies Inc 財務諸表

Annual	2023
収益:	$18 000.00
総利益:	$-343 000 (-1 905.56 %)
EPS:	$-3.95

FY	2023
収益:	$18 000.00
総利益:	$-343 000 (-1 905.56 %)
EPS:	$-3.95

FY	2022
収益:	$286 000
総利益:	$229 000 (80.07 %)
EPS:	$-6.40

FY	2021
収益:	$441 000
総利益:	$242 000 (54.88 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Biosig Technologies Inc

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.